Immuno-Oncology Resource Center
Immuno-Oncology Resource Center
October 10, 2019
1 min read

Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Phase 1 dose-escalation clinical trial to determine the phase 2 dose of autologous TIL 1383I TCR gene-modified T cells using a retrovirus for patients with advanced melanoma.